查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047014

頭孢氯肟市場－全球產業規模、佔有率、趨勢、機會、預測：銷售管道、等級、最終用途、地區和競爭格局分類，2021-2031年

Cefuroxime Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By Grade, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球Cefuroxime市場預計將從 2025 年的 5.4634 億美元成長到 2031 年的 7.4649 億美元，複合年成長率為 5.34%。

市場以Cefuroxime為核心，頭孢呋辛是一種廣泛使用的第二代頭孢菌素類抗生素，用於治療多種細菌感染疾病，包括呼吸道、皮膚和泌尿器官系統感染。推動市場成長的關鍵因素包括全球感染疾病率的上升，以及Cefuroxime因其對革蘭氏陽性菌和革蘭氏陰性菌均具有廣譜抗菌活性而在外科手術預防中的廣泛應用。此外，新興經濟體對成熟抗菌療法的穩定需求也持續推動市場表現。例如，歐洲疾病預防控制中心 (ECDC) 的數據顯示，到 2024 年，歐盟 (EU) 系統性抗菌藥物的人口加權平均總消耗量將達到每千人 20.3 個限定日劑量 (DDD)，這凸顯了對這些基本藥物的持續強勁需求。

市場概覽
預測期 2027-2031
市場規模：2025年 5.4634億美元
市場規模：2031年 7.4649億美元
複合年成長率：2026-2031年 5.34%
成長最快的細分市場 直接的
最大的市場 北美洲

然而，阻礙市場成長的一大障礙是日益嚴重的抗菌藥物抗藥性（AMR）問題，這威脅到BETA-內醯胺類抗生素的療效。隨著細菌發展出諸如產生BETA-內醯胺酶等抗藥性機制來中和這些藥物，醫療專業人員正在實施越來越嚴格的抗菌藥物合理使用方案。這些監管和臨床變化導致頭孢菌素類抗生素（如Cefuroxime）的處方更加有限和謹慎，在許多情況下，醫生傾向於優先選擇窄頻譜替代藥物和備用療法。這可能會抑製成熟市場的銷售量成長。因此，製造商需要在維持供應鏈穩定的同時，適應抗藥性模式日益決定治療方案的環境。

市場促進因素

全球細菌性呼吸道感染疾病率的不斷上升顯著推高了Cefuroxime的需求，該藥物已成為治療社區型肺炎和支氣管炎的主要藥物。臨床醫師經常開立這種第二代頭孢菌素，尤其是在一線治療藥物青黴素療效不佳的情況下，因為其對肺炎鏈球菌和流感嗜血桿菌等常見病原體具有顯著療效。呼吸道疾病的增加直接導致住院和門診病人的處方量增加，迫使生產者擴大生產以滿足日益成長的公共衛生需求。 2025年11月，國際呼吸學會論壇報告稱，2023年全球有250萬人死於肺炎，比2021年增加了19%，凸顯了有效抗生素干預的緊迫性。

同時，尿道感染和皮膚感染疾病負擔的加重進一步推動了市場擴張，因為Cefuroxime仍然是治療單純性膀胱炎和軟組織感染疾病的重要選擇。隨著這些疾病發生率的上升，且常伴隨抗藥性菌株的出現，人們需要頻譜併發症，即使在標靶性較強的抗生素無效的情況下也能提供可靠的療效。世界衛生組織（WHO）於2025年10月發布的《2025年全球抗菌素抗藥性監測報告》（GLASS報告）顯示，2023年全球三分之一的尿道感染是由抗藥性細菌引起的，這凸顯了醫療系統利用Cefuroxime等有效治療方法的壓力。這種持續的感染疾病負擔支撐了已開發地區和新興地區強勁的消費趨勢，英國衛生安全局指出，2019年至2024年間，英格蘭基層醫療的抗生素使用量增加了10.7%，反映出主要市場抗生素使用的持續成長。

市場挑戰

抗菌藥物抗藥性（AMR）日益嚴重的威脅是全球Cefuroxime市場商業性成長的主要障礙。Cefuroxime是一種第二代頭孢菌素，但對產生BETA-內醯胺酶的細菌病原體的敏感性正在持續降低。 BETA-內醯胺酶是一種防禦機制，能夠中和頭孢呋辛的治療效果。隨著這些生物抗藥性模式的日益普遍，Cefuroxime的臨床效用正在下降，醫療專業人員開始選擇光譜較窄的頻譜藥物或備用抗生素。此外，嚴格的抗菌藥物合理使用計劃進一步加劇了這一趨勢，這些計劃系統性地限制處方量以維持Cefuroxime的剩餘療效，導致受益患者數量直接減少，並影響生產商的持續收入。

這一市場萎縮趨勢得到了令人擔憂的監測數據的支持，這些數據涉及先前曾使用此類藥物治療的主要病原體。 2025年，世界衛生組織（WHO）報告稱，全球監測顯示，在多個報告地區，分離出的大腸桿菌對頭孢菌素的抗藥性超過40%。由於抗藥性機制通常會導致對多代BETA-內醯胺類抗生素的交叉抗藥性，這種高盛行率使得Cefuroxime對相當一部分常見感染疾病無效。療效的下降導致該藥物的市場佔有率必然減少，因為處方醫生被迫避免使用Cefuroxime，即使是對先前敏感的病原體也是如此，從而抑制了該藥物在成熟和發展中醫療體系中的銷售量成長。

市場趨勢

全球頭孢呋辛市場的生產商正日益在其原料藥（API）生產中採用綠色化學原則，以減少BETA-內醯胺類抗生素生產對環境的影響。這一新趨勢包括從傳統的化學合成轉向酶法工藝，從而顯著減少溶劑的使用和廢棄物的產生，同時提高產率和純度。隨著藥品污染物監管框架的日益嚴格，這種永續的生產實踐正成為一項重要的競爭優勢。例如，Centrient Pharmaceuticals公司於2025年6月發布的《2024年ESG報告》強調，其專有的抗生素酶法生產技術與傳統化學製程相比，可減少63%的碳足跡，這充分證明了此類環保方法的工業可行性。

同時，新興市場學名藥產品組合的擴張正在改變競爭格局。這是因為企業正試圖應對成熟市場日益成長的成本壓力。歐洲和北美不斷上漲的營運成本迫使學名藥生產商透過進入亞洲和拉丁美洲等高需求市場來實現收入來源多元化。這種策略轉變將使企業能夠利用規模經濟，並在第二代頭孢菌素日益商品化的情況下保持盈利。根據歐洲藥品協會（Medicines for Europe）2025年12月發表的報導《歐洲抗生素短缺是政策失敗，亟需改革》的文章，由於生產成本飆升，該行業的工業價格上漲了31.6%，而這種財務負擔正在加速企業將資源戰略性地重新配置到更具韌性的新興市場產品組合中。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球頭孢氯肟市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 等級（乙醯基，鈉）
    • 依用途分類（支氣管炎、淋病、萊姆病、皮膚感染疾病、耳部感染疾病、咽喉感染疾病、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美頭孢氯肟市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲頭孢氯肟市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區頭孢氯肟市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：頭孢氯肟在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：頭孢氯肟在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球頭孢氯肟市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Aurobindo Pharma Ltd.
  • Zydus Lifesciences Ltd.
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals PLC
  • Mylan NV

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28276

The Global Cefuroxime Market is projected to expand from USD 546.34 Million in 2025 to USD 746.49 Million by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 5.34%. This market revolves around Cefuroxime, a widely prescribed second-generation cephalosporin antibiotic used to treat diverse bacterial infections, including those affecting the respiratory tract, skin, and urinary system. Key drivers for this growth include the increasing worldwide occurrence of infectious diseases and Cefuroxime's extensive use in surgical prophylaxis, attributed to its broad-spectrum effectiveness against both Gram-positive and Gram-negative bacteria. Furthermore, the consistent demand for established antimicrobial therapies within emerging economies continues to strengthen market performance. For instance, data from the European Centre for Disease Prevention and Control indicated that in 2024, the population-weighted mean total consumption of antibacterials for systemic use across the European Union was 20.3 defined daily doses per 1,000 inhabitants per day, highlighting the significant and ongoing demand for these crucial medications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 546.34 Million
Market Size 2031USD 746.49 Million
CAGR 2026-20315.34%
Fastest Growing SegmentDirect
Largest MarketNorth America

However, a major obstacle hindering market growth is the escalating problem of antimicrobial resistance (AMR), which threatens the effectiveness of beta-lactam antibiotics. As bacteria develop resistance mechanisms, such as beta-lactamase production, to neutralize these drugs, healthcare providers are increasingly implementing stringent antimicrobial stewardship programs. This regulatory and clinical shift encourages the limited and more judicious prescription of cephalosporins like Cefuroxime, often favoring narrower-spectrum alternatives or reserve-line treatments, which could restrict volume growth in well-established markets. Consequently, manufacturers must manage both maintaining a stable supply chain and adapting to an environment where resistance patterns increasingly dictate treatment protocols.

Market Driver

The rising global incidence of bacterial respiratory tract infections significantly boosts demand for Cefuroxime, positioning it as a primary treatment for conditions like community-acquired pneumonia and bronchitis. Clinicians frequently prescribe this second-generation cephalosporin due to its proven effectiveness against common pathogens such as Streptococcus pneumoniae and Haemophilus influenzae, especially in cases where first-line penicillins might be inadequate. This increase in respiratory illness directly translates into higher prescription volumes in both hospital and outpatient settings, prompting manufacturers to scale up production to address intensifying public health requirements. The Forum of International Respiratory Societies reported in November 2025 that pneumonia was responsible for 2.5 million deaths globally in 2023, marking a 19% increase from 2021, which underscores the urgent need for effective antibiotic interventions.

Simultaneously, the growing burden of urinary tract and skin infections further fuels market expansion, as Cefuroxime remains an essential option for managing uncomplicated cystitis and soft tissue infections. The increasing occurrence of these conditions, often complicated by resistant bacterial strains, necessitates the deployment of broad-spectrum agents that provide dependable results when more targeted antibiotics fail. According to the World Health Organization's Global Antibiotic Resistance Surveillance (GLASS) Report 2025, published in October 2025, one in three urinary tract infections worldwide in 2023 were caused by bacteria resistant to antibiotics, emphasizing the pressure on healthcare systems to utilize effective treatments like Cefuroxime. This persistent infection burden supports robust consumption trends across both developed and emerging regions, with the UK Health Security Agency noting a 10.7% increase in primary care antibiotic use in England between 2019 and 2024, reflecting the ongoing expansion of antimicrobial utilization in key markets.

Market Challenge

The escalating threat of antimicrobial resistance (AMR) poses a substantial obstacle to the commercial growth of the Global Cefuroxime Market. Cefuroxime, as a second-generation cephalosporin, is increasingly susceptible to bacterial pathogens that produce beta-lactamase enzymes, which are defense mechanisms that neutralize the drug's therapeutic action. As these biological resistance patterns become more widespread, the clinical utility of Cefuroxime diminishes, leading healthcare providers to opt for narrower-spectrum alternatives or reserve-line antibiotics. This shift is solidified by strict antimicrobial stewardship programs, which systematically limit Cefuroxime prescription volumes to preserve its remaining efficacy, thereby directly reducing the available patient population and impacting recurring revenue for manufacturers.

This market erosion is corroborated by concerning surveillance data on key pathogens traditionally treated with this class of drugs. The World Health Organization reported in 2025 that global monitoring indicated resistance to cephalosporins in Escherichia coli isolates exceeded 40% across various reported regions. Given that resistance mechanisms often grant cross-protection against multiple generations of beta-lactams, this high prevalence renders Cefuroxime ineffective for a significant portion of common infections. Such reduced efficacy compels a decrease in the drug's achievable market share, as prescribers are required to bypass Cefuroxime for pathogens that were historically susceptible, thereby curbing the drug's volume growth in both established and developing healthcare systems.

Market Trends

Manufacturers in the Global Cefuroxime Market are increasingly adopting Green Chemistry Principles in API Manufacturing to lessen the environmental footprint associated with producing beta-lactam antibiotics. This emerging trend involves a strategic shift from conventional chemical synthesis methods to enzymatic processes, which significantly reduce the use of solvents and the generation of waste, while simultaneously enhancing yield purity. Such sustainable manufacturing practices are becoming a crucial competitive advantage as regulatory frameworks governing pharmaceutical pollutants become more stringent. For example, Centrient Pharmaceuticals' ESG Report 2024, released in June 2025, highlighted that their proprietary enzymatic technology for antibiotic production achieves a 63% reduction in carbon footprint compared to traditional chemical processes, demonstrating the industrial viability of these eco-friendly approaches.

Concurrently, the Expansion of Generic Product Portfolios in Emerging Markets is transforming the competitive landscape, as companies aim to counteract rising cost pressures experienced in established regions. Increasing operational expenses in Europe and North America are compelling generic manufacturers to diversify their revenue streams by entering high-volume markets in Asia and Latin America. This strategic pivot enables firms to capitalize on economies of scale and maintain profitability despite the commoditization of second-generation cephalosporins. According to Medicines for Europe, in a December 2025 article titled 'Europe's antibiotic shortages are a policy failure requiring urgent reform,' the sector faced a 31.6% increase in industrial prices due to escalating production costs, a financial strain that is accelerating the strategic reallocation of resources towards more resilient emerging market portfolios.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Aurobindo Pharma Ltd.
  • Zydus Lifesciences Ltd.
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.

Report Scope

In this report, the Global Cefuroxime Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cefuroxime Market, By Sales Channel

  • Direct
  • Indirect

Cefuroxime Market, By Grade

  • Axetil
  • Sodium

Cefuroxime Market, By End Use

  • Bronchitis
  • Gonorrhea
  • Lyme Disease
  • Skin Infection
  • Ear Infection
  • Throat Infection
  • Others

Cefuroxime Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cefuroxime Market.

Available Customizations:

Global Cefuroxime Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cefuroxime Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By Grade (Axetil, Sodium)
    • 5.2.3. By End Use (Bronchitis, Gonorrhea, Lyme Disease, Skin Infection, Ear Infection, Throat Infection, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Cefuroxime Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By Grade
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cefuroxime Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By Grade
        • 6.3.1.2.3. By End Use
    • 6.3.2. Canada Cefuroxime Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By Grade
        • 6.3.2.2.3. By End Use
    • 6.3.3. Mexico Cefuroxime Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By Grade
        • 6.3.3.2.3. By End Use

7. Europe Cefuroxime Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By Grade
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cefuroxime Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By Grade
        • 7.3.1.2.3. By End Use
    • 7.3.2. France Cefuroxime Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By Grade
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Cefuroxime Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By Grade
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Cefuroxime Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By Grade
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Cefuroxime Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By Grade
        • 7.3.5.2.3. By End Use

8. Asia Pacific Cefuroxime Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By Grade
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cefuroxime Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By Grade
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Cefuroxime Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By Grade
        • 8.3.2.2.3. By End Use
    • 8.3.3. Japan Cefuroxime Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By Grade
        • 8.3.3.2.3. By End Use
    • 8.3.4. South Korea Cefuroxime Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By Grade
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Cefuroxime Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By Grade
        • 8.3.5.2.3. By End Use

9. Middle East & Africa Cefuroxime Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By Grade
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cefuroxime Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By Grade
        • 9.3.1.2.3. By End Use
    • 9.3.2. UAE Cefuroxime Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By Grade
        • 9.3.2.2.3. By End Use
    • 9.3.3. South Africa Cefuroxime Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By Grade
        • 9.3.3.2.3. By End Use

10. South America Cefuroxime Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By Grade
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cefuroxime Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By Grade
        • 10.3.1.2.3. By End Use
    • 10.3.2. Colombia Cefuroxime Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By Grade
        • 10.3.2.2.3. By End Use
    • 10.3.3. Argentina Cefuroxime Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By Grade
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cefuroxime Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Teva Pharmaceutical Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Sun Pharmaceutical Industries Ltd.
  • 15.4. Cipla Limited
  • 15.5. Aurobindo Pharma Ltd.
  • 15.6. Zydus Lifesciences Ltd.
  • 15.7. Pfizer Inc.
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. Hikma Pharmaceuticals PLC
  • 15.10. Mylan N.V.

16. Strategic Recommendations

17. About Us & Disclaimer